Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit
Kindred Biosciences (NASDAQ: KIN), a biopharmaceutical company dedicated to improving pet health, will present at the BofA Securities Animal Health Virtual Summit on February 25.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kindred Biosciences (NASDAQ: KIN), a biopharmaceutical company dedicated to improving pet health, will present at the BofA Securities Animal Health Virtual Summit on February 25. CEO Dr. Richard Chin will deliver a presentation via webcast at 10:50 AM ET, followed by virtual one-on-one meetings with investors. The company aims to develop safe, effective biologics for pets based on successful human therapeutics. An archived version of the webcast will be available for 30 days on the KindredBio website.
Details
News Market Reaction – KIN
The recorded move for KIN in the trading session of this news was -3.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25.
Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones.
An archived version of the above webcast will be available for 30 days on the KindredBio website.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, visit: www.kindredbio.com
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-the-bofa-securities-animal-health-virtual-summit-301229317.html
SOURCE Kindred Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.